A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

NCT01682161 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Paliperidone palmitate

Sponsor

Janssen Korea, Ltd., Korea